In this edition, we highlight how Radiopharmaceuticals are framed as a mainstream oncology platform, underpinned by theranostics that pair diagnostic imaging and therapeutic radionuclides on the same biomarker (e.g., SSTR, PSMA) and are now expanding into new targets such as FAP, CAIX, and GPCRs. The deck emphasizes that isotope production, especially Alpha emitters like Ac‑225 and Pb‑212, is concentrated in a limited number of reactors, making supply security a critical competitive advantage and a key constraint on pipeline expansion. 

In parallel, US FDA and EMA have released new guidance on radiopharmaceutical quality, dosing, and clinical evaluation, while more than $13B in Radiopharma M&A and licensing since 2023 signals strong capital alignment. Ultimately, the winners are expected to be those who vertically integrate manufacturing, isotope supply, logistics, and treatment networks to navigate just‑in‑time supply chains, capacity‑constrained infusion grids, and complex reimbursement systems